Cordis/Advanced Cell Technology
This article was originally published in The Gray Sheet
Executive Summary
The Biologics Delivery Systems group of Johnson & Johnson/Cordis will supply catheters for administering Advanced Cell Technology's stem cell therapy for treatment of heart failure in a Phase II clinical trial, ACT announces March 5. The myoblast therapy involves transplanting stem cells derived from a patient's leg muscle into scarred heart tissue to help rebuild the heart muscle and prevent progression of congestive heart failure. The trial will use the Cordis group's NOGA cardiac navigation system and MyoStar injection catheter. Medtronic and Genzyme are also collaborating on catheter delivery of myoblast treatment (1"The Gray Sheet" June 7, 2004, p. 13)